# Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

> **NCT02888379** · PHASE2 · COMPLETED · sponsor: **Topivert Pharma Ltd** · enrollment: 77 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** TOP1288
- **DRUG:** Placebo (for TOP1288)

## Key facts

- **NCT ID:** NCT02888379
- **Lead sponsor:** Topivert Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-06-28
- **Final completion:** 2017-06-28
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888379, "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02888379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*